Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Aulos Bioscience, Inc.
Sotio Biotech Inc.
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Mayo Clinic
University of Pittsburgh
Incyte Corporation
University of Arizona
Pfizer
Sensei Biotherapeutics, Inc.
Incyte Corporation
University of Virginia
Incyte Corporation
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
UNICANCER
Checkpoint Therapeutics, Inc.
Vincerx Pharma, Inc.
Mayo Clinic
ImaginAb, Inc.
Arcus Biosciences, Inc.
University of Florida
Massachusetts General Hospital
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Ludwig Institute for Cancer Research
Incyte Corporation
Genocea Biosciences, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
MultiVir, Inc.
University of Southern California
Emory University
Yale University